|
News from 2008
Read more recent news.
December 17, 2008
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) an integrated biotechnology and wellness company, today announced the appointment of Dr. Kyl Smith to its Scientific Board.
HST Global, Inc. is proud to announce the appointment of Dr. Kyl Smith to its Scientific Advisory Board. Dr. Smith has enjoyed a high position of visibility in the world of natural medicine. He is a noted researcher, inventor, lecturer, author and scientist, and is well- known as the inventor of Focus Factor®, the number-one selling brain support product in North America for the last seven years. Dr. Kyl has appeared on hundreds of radio and television programs across the country in the last decade – he’s the author of the acclaimed Brighter Mind® book series, and is a popular speaker providing Continuing Education programs for physicians. His passion is teaching doctors how to utilize and integrate nutritional therapies to improve cognitive function in practice based on clinical research as published in peer-reviewed literature.
Professionally, Dr. Kyl received his doctorate of Chiropractic in 1993, and has since engaged in nutrition and natural medicine research. Most notably, in 2001 – with the help of some of the top scientists in the world, including a former senior scientist for the American Medical Association – Dr. Kyl filed a Health Claim Petition for Phosphatidylserine, which was approved by the Food and Drug Administration (FDA) in 2002.
This is an unprecedented accomplishment; it represents the first Health Claim for cognitive function to be approved in the FDA’s history. As a result, Dr. Kyl received the James Lind Scientific Achievement Award, which acknowledges the accomplishments of those who have contributed to the scientific advancement of natural medicine and are helping to reshape the very structure of American health care.
Read the full news release on BusinessWire.com
November 25, 2008
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) an integrated biotechnology and wellness company, today announced plans for the first quarter fiscal 2009.
The growing acceptance of alternative cancer treatments worldwide has placed HST Global in perfect position to launch a wholly owned division dedicated to opening our own brand of Cancer Treatment Centers. While we continue to look for in-licensing pre-clinical drug candidates, this strategy will enable the company to address the challenges individuals face in the treatment of cancer in the later stages.
Ronald Howell, President and CEO of HST Global, Inc. stated "There is a growing population of individuals experiencing the lack of available alternatives in treating late stage cancer. We have been working with a number of highly visible Physicians that are and have developed successful protocols that are meeting with success in the treatment of this population. As such, we will begin opening a privately branded chain of Cancer Treatment Centers strategically positioned around the world through a new wholly owned subsidiary."
Mr. Howell went on to say, "The distribution channel established through our Cancer Treatment Centers will serve as a platform for implementing existing technologies and serve to identify appropriate communities for treatment with new and emerging drug candidates as they become available."
Read the full news release on BusinessWire.com
September 18, 2008
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) a development stage biotechnology company, today announced that it has asked EBITDA Capital to assist in the selection of its FDA legal team and EBITDA Capital has assigned the process to Roman Buhler.
Mr. Buhler served for 14 years as Counsel to the US House of Representatives Committee on House Administration, and currently runs his own lobbying and consulting practice in Washington D.C. He graduated from Stanford University and the University of Southern California Law School. Mr. Buhler is a member of the California Bar.
Mr. Buhler stated, "I am committed to the success of HST Global and to the goal of expediting FDA approval for the treatment it can offer for stage four cancer patients. I am enthusiastic about this mission to help expand opportunities for those who want to obtain treatment with the HST Global solution."
Mr. Chet Noblett, Managing Partner, at EBITDA Capital stated, "I have been closely associated with Roman for many years and he is one of the most thorough individuals that I know. He not only understands the process of government but with his solid judgment and intellect he makes accurate and impactful decisions and recommendations. I am excited that he has accepted the assignment."
Read the full news release on BusinessWire.com
August 27, 2008
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) is pleased to announce that it has, through its contracted partner EBITDA Capital LLC of Newport Beach California and its group of associates, commenced negotiations with the Chinese Government for both direct investment and a license for their treatment protocols.
Mr. Ron Howell, CEO and President of HST Global stated, Through the use of the EBITDA Capital resources we at HST Global can focus on the issue of bringing awareness of our treatment and solution for late stage cancer treatment to the Chinese community. We want to insure that our treatment is being given every opportunity to be recognized as the medical solution alternative of choice throughout the world.
One of EBITDA Capitals tasks was to develop a working relationship with the Chinese Government and Congressman Sarpalius just completed his initial trip to establish the working relationship. After his trip he reported, Every community in China has a cancer center and the Chinese government is committed to treatment of the disease. Congressman Sarpalius has commitments from both the government and privately sanctioned investors to commence negotiations with HSTC for both direct investment into HSTC and a license for the treatment protocols. The company expects to host the Chinese delegation within the next thirty days. Ms. Jenny Guo, of Advantage Associates, will host the delegation to be received by Ron Howell in the United States.
Read the full news release on BusinessWire.com
August 20, 2008
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC)
is pleased to announce that it has contracted EBITDA Capital LLC of Newport Beach California and its group of associates to assist HST-Global’s efforts in working toward an overall corporate strategy.
Former United States Congressman Bill Sarpalius, the President and CEO of Advantage Associates International, based in Washington DC, has been assigned the opportunity to interface with the political community in Washington DC. As President of his Advantage Associates, Congressman Sarpalius says, "we are excited to be in a position to raise the awareness of both the public and members of the government about HST’s treatment solution. The opportunity of bringing a treatment for late stage cancer is something which we all want to see expanded and made use of in the treatment community."
Mr. Ron Howell, CEO and President of HST Global retained EBITDA Capital and says, "through the use of the EBITDA Capital resources we at HST Global can focus on the issue of bringing awareness of our treatment and solution for late stage cancer treatment. We want to insure that our treatment is being given every opportunity to be recognized as the medical solution alternative of choice."
"HST has worked to develop a complete strategy for the success of its program and treatment and is now moving toward a more public awareness platform. We believe that EBITDA and its associates, such as Advantage Associates, will help us get this done," stated Mr. Howell.
Read the full news release on BusinessWire.com
July 11, 2008
HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC), a development stage biotechnology company, today announced the appointment of Dr. James W. Forsythe to their Board of Directors. Dr. Forsythe brings over thirty years of medical and research experience to complement the business background of current board members.
"Dr. Forsythe’s strong ties to the medical and research community will be a valuable asset to our board," said Ron Howell, CEO and President of HST Global, Inc. "James will be instrumental in helping us increase our visibility of new technology and research applications." Currently, Dr. Forsythe is an Associate Professor of Medicine and Pathology, ...
Read the full news release on BusinessWire.com |
